Clinical trials: Gemigliptin
Type2 Diabetes
Bioequivalence Study for Gemigliptin/Metformin 50/1000 mg and Coadministration of Gemigliptin 50 mg and Metformin 1000 mg.
[Objectives]Primary: To determine and compare the rate and extent of absorption of gemigliptin/metformin hydrochloride sustained release 50/1000 mg FDC tablet (Zemimet® SR Tab.
- Trial name
- NCT04050098
- Testing
- gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release, Gemigliptin tartrate sesquihydrate and metformin
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- LG Chem
Healthy
Pharmacokinetic Drug Interaction Study Between Gemigliptin and Glimepiride in Healthy Male Subjects
The objective of the study was to investigate the pharmacokinetic drug interaction between gemigliptin and glimepiride in healthy male subjects after oral administration concomitantly and each alone.
- Trial name
- NCT01768455
- Testing
- Gemigliptin and Glimepiride, Glimepiride
- Where
- South Korea
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Type 2 Diabetes Mellitus
Observational Study of Triple Combination Therapy of Zemidapa Tab. and Metformin in Type 2 Diabetes Mellitus Patients
The aim of this study is to evaluate the effectiveness and safety of the triple combination therapy of Zemidapa Tab. and Metformin in patients with type 2 diabete mellitus
- Trial name
- NCT06495281
- Where
- South Korea
- Volunteers
- 2,044 people
- Sponsor
- LG Chem
Type 2 Diabetes Mellitus
An Observational Study to Evaluate Cardiovascular Outcomes of T2DM PatientsTreated With Gemigliptin
The primary objective of the study is to investigate cardiovascular safety of gemigliptin by evaluating the time until patients report with major adverse cardiovascular events (MACE) in T2DM patients treated with gemigliptin.
- Trial name
- NCT02290301
- Testing
- gemigliptin
- Where
- South Korea
- Volunteers
- 5,180 people
- Sponsor
- LG Life Sciences
Type 2 Diabetes
Bioequivalence Study for Fixed Dose Combination Zemimet® SR Tab. 50/1000 and Coadministration of Gemigliptin 50 mg and Metformin 1000 mg.
To determine and compare the rate and extent of absorption of gemigliptin/metformin hydrochloride sustained release 50/1000 mg FDC tablet (Zemimet® SR Tab.
- Trial name
- NCT04317703
- Testing
- Gemigliptin tartrate sesquihydrate and metformin, gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release
- Where
- Thailand
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- LG Chem
Healthy
Study for Investigate the Pharmacokinetic Drug Interactions Between Gemigliptin and Rosuvastatin
Investigate the pharmacokinetic drug interactions between gemigliptin and rosuvastatin in healthy subjects
- Trial name
- NCT01823133
- Testing
- gemigliptin only, rosuvastatin only, gemigliptin and rosuvastatin
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Type 2 Diabetes Mellitus
Gemigliptin, Dapagliflozin, Empagliflozin DDI Study
gemigliptin,SGLT-2i DDI study
- Trial name
- NCT03565458
- Testing
- Gemigliptin, Dapagliflozin, Empagliflozin
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- LG Chem
Endothelial Function, Type 2 Diabetes
Effect of Gemigliptin or Acarbose on Endothelial Function in Type 2 DM Patients
This is a phase 4, single center, randomized, open-labeled study. The primary objective of the study is to compare effect of gemigliptin and acarbose on endothelial function.
- Conditions
- Endothelial Function, Type 2 Diabetes, Gemigliptin, Acarbose
- Trial name
- NCT02500329
- Testing
- Gemigliptin, Acarbose
- Where
- South Korea
- Volunteers
- 54 people
- Sponsor
- Seoul National University Hospital
Type 2 Diabetes Mellitus
Trial to Evaluate the Efficacy and Safety of Gemigliptin Compared With Placebo Added on Insulin Alone or on Insulin in Combination With Metformin in Type 2 DM (ZEUS II Study)
The objective of this study is to evaluate the efficacy and safety of gemigliptin 50 mg orally administered once daily for 24 weeks compared with placebo in patients with type 2 diabetes mellitus who have inadequate glycemic…
- Trial name
- NCT02831361
- Testing
- Gemigliptin, Metformin, Diet/exercise questionnaire
- Volunteers
- 290 people
- Sponsor
- LG Life Sciences
Type 2 Diabetes Mellitus
Effects of Gemigliptin Versus Sitagliptin or Glimepiride With Metformin on Glucose Variability(MAGE, Glucose SD) Patients With Type 2 DM(STABLE Study)
To compare efficacy and safety of initial combination therapy of Gemigliptin versus Sitagliptin or Glimepiride with Metformin on Glucose Variability(MAGE, Glucose SD) in Patients With Type 2 Diabetes Mellitus.
- Trial name
- STABLE (NCT01890629)
- Testing
- Gemigliptin + Metformin / Sitagliptin + Metformin / Glimepiride + Metformin
- Where
- South Korea
- Volunteers
- 69 people
- Sponsor
- LG Life Sciences
Healthy
BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone.
This study is to evaluate the safety/tolerability and pharmacokinetics of the combinations of gemigliptin 50mg and metformin HCl extended release 1000mg in comparison to each component administered in healthy male volunteers.
- Trial name
- NCT02056600
- Testing
- gemigliptin and metformin HCl extended release, gemigliptin/metformin HCl sustained release
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences